Adamis Pharmaceuticals is a specialty biopharmaceutical company. Co. develops and commercializes products in the therapeutic areas of respiratory disease and allergy. Co.'s products and product candidates include: Symjepi Injection 0.3mg for the treatment of acute allergic reactions and anaphylaxis; Symjepi Injection 0.15mg for the treatment of anaphylaxis for patients weighing 33-65 pounds; a naloxone injection product candidate for the treatment of opioid overdose; and, a beclomethasone metered dose inhaler and fluticasone dry powder inhaler for the treatment of asthma. Co. also provides prescription compounded medications, to patients, physician, and among others throughout the U.S. According to our ADMP split history records, Adamis Pharmaceuticals has had 1 split.

Adamis Pharmaceuticals (ADMP) has 1 split in our ADMP split history database. The split for ADMP took place on December 13, 2013. This was a 1 for 17 reverse split, meaning for each 17 shares of ADMP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 58.8235294117647 share position following the split.

When a company such as Adamis Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the ADMP split history from start to finish, an original position size of 1000 shares would have turned into 58.8235294117647 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adamis Pharmaceuticals shares, starting with a $10,000 purchase of ADMP, presented on a split-history-adjusted basis factoring in the complete ADMP split history.

Growth of $10,000.00
Without Dividends Reinvested

Start date:

02/23/2009

End date:

02/21/2019

Start price/share:

$0.85

End price/share:

$3.13

Dividends collected/share:

$0.00

Total return:

268.24%

Average Annual Total Return:

13.92%

Starting investment:

$10,000.00

Ending investment:

$36,812.88

Years:

10.00

ADMP Split History Table

Date

Ratio

12/13/2013

1 for 17

Healthcare Stock Splits

ADMP is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.